ABSTRACT
OBJECTIVE: COVID-19 may cause thrombosis in both venous and arterial systems. Familiarity with the signs and symptoms of thrombosis and its treatment is essential in treating COVID-19 infection and its complications. D-Dimer and mean platelet volume (MPV) are measurements related to the development of thrombosis. This study investigates whether MPV and D-Dimer values could be used to determine the risk of thrombosis and mortality in the COVID-19 early stages. PATIENTS AND METHODS: 424 patients who were COVID-19 positive, according to the World Health Organization (WHO) guidelines, were randomly and retrospectively included in the study. Demographic and clinical characteristics such as age, gender, and length of hospitalization were obtained from the digital records of participants. Participants were divided into living and deceased groups. The patients' biochemical, hormonal, and hematological parameters were analyzed retrospectively. RESULTS: White blood cells (WBC), neutrophils, and monocytes were significantly different in the two groups (p-value <0.001), and their values were lower in the living group than in the deceased group. MPV median values did not differ according to prognosis (p-value = 0.994). While the median value was 9.9 in the survivors, it was 10 in the deceased. Creatinine, procalcitonin, ferritin, and the number of hospitalization days in living patients were significantly lower than in patients who died (p-value <0.001). Median values of D-dimer (mg/L) differ according to prognosis (p-value <0.001). While the median value was 0.63 in the survivors, it was found as 438 in the deceased. CONCLUSIONS: Our results did not show any significant relationship between the mortality of COVID-19 patients and their MPV levels. However, a significant association between D-Dimer and mortality in COVID-19 patients was observed.
Subject(s)
COVID-19 , Thrombosis , Humans , Mean Platelet Volume , Prognosis , Retrospective StudiesABSTRACT
Objective: Coronavirus disease-2019 (COVID-19) infection is more severe and mortality is more common in patients with malignancy. Methods: We evaluated the clinical course of COVID-19 infection in patients with chronic myeloid leukemia. 327 patients with chronic myeloid leukemia were analyzed and 21 cases with COVID-19 infection were included in this study. The complaints at the time of admission, laboratory and clinical findings, drugs used for treating COVID-19 infection of these patients were examined. Results: The mean age of 21 patients was 45 +/- 15.85 years;8 (38.1%) of the cases were male and 13 (61.9%) were female. All of these cases had chronic phase chronic myeloid leukemia. The most common complaints at the time of admission to hospital were weakness (66.7%), muscle and/or joint pain (57.1%), sore throat (42.9%). Four (19%) cases had pulmonary involvement and 4 (19%) cases were hospitalized. None of our patients needed intensive care unit admission and mechanical ventilation support. No cases died from COVID-19 infection. Conclusion: The chronic myeloid leukemia patients with COVID-19 infection had a mild clinical course of COVID-19 infection. This could depend on the normal hematological parameters of chronic myeloid leukemia patients or using tyrosine kinase inhibitors.
ABSTRACT
Introduction: SARS-CoV-2 binds to angiotension coverting enzyme-2 (ACE-2) receptors on the surface of the the host cells. ACE receptors are found in bone marrow (BM). SARS-CoV-2 can reduce hematopoiesis in all cell lines by infecting the BM cells directly and by changing the local RAS in addition to the suppression by cytokines during the course of COVID-19. However, there has been no study that could demonstrate the presence of SARS-CoV-2 in BM. Therefore in this study, we aim to demonstrate SARS-CoV-2 in the BM and investigate the changes in the BM of critically ill COVID-19 patients. Materials and method: This study is single center research and six critically ill COVID-19 patients were included in the study. Flowcytometry and RT-PCR were studied in BM aspiration samples. Histopathological evaluation of bone marrow biopsy materials was performed. Results: The most striking finding in BM was reactive plasmacytosis. CD4 / CD8 ratio of 3 patients was reversed (<1). There was an average of 90% CD14+ CD16- classical monocyte. In 1 patient SARS-CoV-2 was demonstrated in BM cells by RT-PCR. Conclusion: To the best of our knowledge, this is the first study which demonstrated SARS-CoV-2 in the BM. In our study revealed an increase in polyclonal plasma cells, CD14+ CD64+ CD68+ active monocytes in BM and demonstrated SARS-CoV-2 in the BM by RT-PCR analysis in 1 patient. Evaluation of flowcytometric analysis of the BM in COVID-19 patients may help the scientists to understand the pathogenesis of SARS-CoV-2 and its effects on hematopoietic cells. © 2021 A. CARBONE Editore. All rights reserved.